5 results about "Mrna gene expression" patented technology

A processor is configured to implement a machine learning model that is trained to select transcripts in blood for distinguishing neurodegenerative diseases. The algorithm is developed via machine learning and leverages concepts associated with blood-based changes in mRNA gene expression for differentiating patients of any neurodegenerative disease regardless of the proteins or their post-translational modifications occurring in disease.

The present invention discloses the use of Avn Anthramides C (Avn C) as an inducer of chondrocytic differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapy. By employing Avn C treatment, MSCs exhibit enhanced chondrocytic differentiation and elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably Collagen Type II (COL2A1). Furthermore, when Avn C is used in combination with Chondroitin Sulfate (CS), a synergistic effect is observed, leading to upregulation of the transcriptional activity state of SOX9, a key regulator of chondrogenesis. The disclosed invention shows significant improvements in mRNA gene expression (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).

A processor is configured to implement a machine learning model that is trained to select transcripts in blood for distinguishing neurodegenerative diseases. The algorithm is developed via machine learning and leverages concepts associated with blood-based changes in mRNA gene expression for differentiating patients of any neurodegenerative disease regardless of the proteins or their post-translational modifications occurring in disease.

The present invention discloses an application of Avenanthramide C (Avn C) as an inducer of chondrocyte differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapies. By employing Avn C treatments, MSCs exhibit enhanced chondrocyte differentiation with elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably collagen type 2 (COL2A1). Moreover, a synergistic effect is observed when Avn C is used in combination with Chondroitin Sulfate (CS), resulting in the upregulation of the transcriptionally active state of SOX9, a crucial regulator of chondrogenesis. The disclosed invention demonstrates significant improvements in mRNA gene expressions (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).

This invention provides a 3'-UTR element and its application in the production of target proteins. The 3'-UTR element comprises: (a) a nucleic acid molecule with a nucleotide sequence as shown in any of SEQ ID NO. 23, SEQ ID NO. 1-SEQ ID NO. 22, SEQ ID NO. 24-SEQ ID NO. 28, and SEQ ID NO. 37; (b) a nucleic acid molecule transcribed using the antisense strand of (a) as a template; or (c) a nucleic acid molecule derived from (a) or (b) by substitution, deletion, or addition of one or more nucleotides in the nucleotide sequence defined by (a) or (b) while retaining the biological function of its derived sequence. This element can stably and significantly enhance mRNA gene expression, providing a powerful tool for the development of mRNA vaccines and the optimization of gene expression in gene therapy.